OR WAIT null SECS
Following a historic National Diabetes Month, which included the approval of teplizumab and the release of STEP TEENS data, some may have expected the diabetes community might have a moment to digest this new information before the next major breakthroughs. This was not the case.
The month of December welcomed the US Food and Drug Administration’s clearance of the Dexcom G7 CGM system for all types of diabetes, the release of data confirming safety and efficacy of SGLT2 inhibitors in pediatric diabetes, updated Standards of Care in Diabetes, and more. In our December 2022 endocrinology month in review, our editorial team provides recaps and links to the most popular content of the month, which, in addition to the aforementioned topics, includes the release of new hypoglycemia guidelines from the Endocrine Society and a special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives where hosts sit down with a member of the writing group for the updated ADA Standards of Care in Diabetes—2023.
Dexcom has announced their Dexcom G7 Continuous Glucose Monitoring (CGM) system has received clearance from the US Food and Drug Administration for people with all types of diabetes aged 2 years and older.
Announced on December 8, the Dexcom G7 boasts an overall MARD of 8.2% and is billed by the company as the most covered CGM on the market.
The Endocrine Society has released a new clinical practice guideline aimed at outlining optimal evidence-based strategies for management of people with diabetes considered to be at high risk for hypoglycemia.
Released on December 7, the guideline, which was created by a multidisciplinary, 10-person team, is expected to be published in the March 2023 print issue of The Journal of Clinical Endocrinology & Metabolism and is cosponsored by major organizations, including the American Association of Clinical Endocrinology and the American Diabetes Association (ADA).
New data suggests empagliflozin (Jardiance) use was associated with significant improvements in glycemic control among pediatric patients with type 2 diabetes.
Announced in a December 7 statement from Eli Lilly and Company, results of the phase 3 DINAMO trial indicate use of empagliflozin was associated with a statistically significant reduction in HbA1c and also with a clinically meaningful reduction in fasting plasma glucose among a population of patients aged 10-17 years of age living with type 2 diabetes.
The ADA has released their updated Standards of Care for 2023 with the goal of providing the diabetes care team within an overview of diabetes management, including updates in diabetes technology, obesity, hypertension, heart failure medication, and lipid management.
The 2023 version of the living document, which has been updated annually since 1989, contains more than 100 updated recommendations within its 17 sections, with new updates highlighting the latest advances in clinical aspects of diabetes management, such as pharmacologic approaches to glycemic treatment, but also related to holistic diabetes management, including patient-first language and the influence of social determinants of health.
Not ones to let an opportunity for a timely spotlight episode pass them by, the hosts of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with Jane Jeffrie Seley, DNP, MPH, a member of the writing group for the ADA’s Standards of Care in Diabetes—2023 at the ADCES DTC 22 the weekend preceding release to discuss the inpatient management section of the document and what went into formulating the recommendations.
Check out the preview below: